D
Zealand Pharma A/S
ZLDPF
$61.52
-$6.48-9.53%
D
Sell
3/14/2023Downgrade
Zealand Pharma A/S (ZLDPF) was downgraded to D- from D on 3/14/2023 due to a significant decline in the growth index. Operating cash flow declined 119.16% from -$17.07M to -$37.4M, earnings per share declined from -$0.4341 to -$0.9218, and EBIT declined 47.6% from -$21.95M to -$32.4M.
Zealand Pharma A/S (ZLDPF) was downgraded to D- from D on 3/14/2023 due to a significant decline in the growth index. Operating cash flow declined 119.16% from -$17.07M to -$37.4M, earnings per share declined from -$0.4341 to -$0.9218, and EBIT declined 47.6% from -$21.95M to -$32.4M.
D
Sell
2/23/2023Upgraded
Zealand Pharma A/S (ZLDPF) was upgraded to D from D- on 2/23/2023 due to an increase in the total return index and volatility index.
Zealand Pharma A/S (ZLDPF) was upgraded to D from D- on 2/23/2023 due to an increase in the total return index and volatility index.
D
Sell
2/8/2023Downgrade
Zealand Pharma A/S (ZLDPF) was downgraded to D- from D on 2/8/2023 due to a decline in the solvency index and valuation index. The quick ratio declined from 3.62 to 1.79, and debt to equity increased from 0.75 to 1.08.
Zealand Pharma A/S (ZLDPF) was downgraded to D- from D on 2/8/2023 due to a decline in the solvency index and valuation index. The quick ratio declined from 3.62 to 1.79, and debt to equity increased from 0.75 to 1.08.
D
Sell
9/20/2022Upgraded
Zealand Pharma A/S (ZLDPF) was upgraded to D from D- on 9/20/2022 due to an increase in the total return index, volatility index and solvency index. Debt to equity declined from 0.96 to 0.75.
Zealand Pharma A/S (ZLDPF) was upgraded to D from D- on 9/20/2022 due to an increase in the total return index, volatility index and solvency index. Debt to equity declined from 0.96 to 0.75.
D
Sell
8/12/2022Upgraded
Zealand Pharma A/S (ZLDPF) was upgraded to D- from E+ on 8/12/2022 due to a major increase in the growth index, volatility index and total return index. EBIT increased 23.19% from -$44.23M to -$33.97M, and earnings per share increased from -$0.998 to -$0.7771.
Zealand Pharma A/S (ZLDPF) was upgraded to D- from E+ on 8/12/2022 due to a major increase in the growth index, volatility index and total return index. EBIT increased 23.19% from -$44.23M to -$33.97M, and earnings per share increased from -$0.998 to -$0.7771.
E
Sell
7/14/2022Downgrade
Zealand Pharma A/S (ZLDPF) was downgraded to E+ from D- on 7/14/2022 due to a decline in the valuation index, total return index and volatility index.
Zealand Pharma A/S (ZLDPF) was downgraded to E+ from D- on 7/14/2022 due to a decline in the valuation index, total return index and volatility index.
D
Sell
6/22/2022Upgraded
Zealand Pharma A/S (ZLDPF) was upgraded to D- from E+ on 6/22/2022 due to an increase in the valuation index and volatility index.
Zealand Pharma A/S (ZLDPF) was upgraded to D- from E+ on 6/22/2022 due to an increase in the valuation index and volatility index.
E
Sell
6/7/2022Downgrade
Zealand Pharma A/S (ZLDPF) was downgraded to E+ from D- on 6/7/2022 due to a decline in the total return index and volatility index.
Zealand Pharma A/S (ZLDPF) was downgraded to E+ from D- on 6/7/2022 due to a decline in the total return index and volatility index.
D
Sell
5/5/2022Upgraded
Zealand Pharma A/S (ZLDPF) was upgraded to D- from E+ on 5/5/2022 due to an increase in the volatility index and valuation index.
Zealand Pharma A/S (ZLDPF) was upgraded to D- from E+ on 5/5/2022 due to an increase in the volatility index and valuation index.
E
Sell
4/20/2022Downgrade
Zealand Pharma A/S (ZLDPF) was downgraded to E+ from D- on 4/20/2022 due to a decline in the total return index, volatility index and valuation index.
Zealand Pharma A/S (ZLDPF) was downgraded to E+ from D- on 4/20/2022 due to a decline in the total return index, volatility index and valuation index.
D
Sell
3/15/2022Downgrade
Zealand Pharma A/S (ZLDPF) was downgraded to D- from D on 3/15/2022 due to a substantial decline in the growth index, solvency index and total return index. Debt to equity increased from 0.01 to 0.72, total revenue declined 50.73% from $16.86M to $8.31M, and earnings per share declined from -$0.7304 to -$0.9982.
Zealand Pharma A/S (ZLDPF) was downgraded to D- from D on 3/15/2022 due to a substantial decline in the growth index, solvency index and total return index. Debt to equity increased from 0.01 to 0.72, total revenue declined 50.73% from $16.86M to $8.31M, and earnings per share declined from -$0.7304 to -$0.9982.
D
Sell
11/15/2021Upgraded
Zealand Pharma A/S (ZLDPF) was upgraded to D from D- on 11/15/2021 due to a noticeable increase in the growth index and volatility index. Earnings per share increased from -$1.1135 to -$0.7304, operating cash flow increased 31.93% from -$53.09M to -$36.14M, and EBIT increased 28.57% from -$46.99M to -$33.57M.
Zealand Pharma A/S (ZLDPF) was upgraded to D from D- on 11/15/2021 due to a noticeable increase in the growth index and volatility index. Earnings per share increased from -$1.1135 to -$0.7304, operating cash flow increased 31.93% from -$53.09M to -$36.14M, and EBIT increased 28.57% from -$46.99M to -$33.57M.
D
Sell
11/8/2021Downgrade
Zealand Pharma A/S (ZLDPF) was downgraded to D- from D on 11/8/2021 due to a noticeable decline in the growth index, solvency index and volatility index. The quick ratio declined from 4.78 to 3.81, earnings per share declined from -$0.9353 to -$1.1135, and EBIT declined 11.17% from -$42.27M to -$46.99M.
Zealand Pharma A/S (ZLDPF) was downgraded to D- from D on 11/8/2021 due to a noticeable decline in the growth index, solvency index and volatility index. The quick ratio declined from 4.78 to 3.81, earnings per share declined from -$0.9353 to -$1.1135, and EBIT declined 11.17% from -$42.27M to -$46.99M.
D
Sell
7/21/2021Downgrade
Zealand Pharma A/S (ZLDPF) was downgraded to D from D+ on 7/21/2021 due to a decline in the volatility index and total return index.
Zealand Pharma A/S (ZLDPF) was downgraded to D from D+ on 7/21/2021 due to a decline in the volatility index and total return index.
D
Sell
7/6/2021Upgraded
Zealand Pharma A/S (ZLDPF) was upgraded to D+ from D on 7/6/2021 due to an increase in the valuation index and volatility index.
Zealand Pharma A/S (ZLDPF) was upgraded to D+ from D on 7/6/2021 due to an increase in the valuation index and volatility index.
D
Sell
6/10/2021Downgrade
Zealand Pharma A/S (ZLDPF) was downgraded to D from D+ on 6/10/2021 due to a decline in the volatility index.
Zealand Pharma A/S (ZLDPF) was downgraded to D from D+ on 6/10/2021 due to a decline in the volatility index.
D
Sell
5/14/2021Upgraded
Zealand Pharma A/S (ZLDPF) was upgraded to D+ from D on 5/14/2021 due to a large increase in the growth index, solvency index and valuation index. Earnings per share increased from -$1.5026 to -$0.9368, the quick ratio increased from 3.71 to 4.78, and EBIT increased 20.04% from -$52.88M to -$42.29M.
Zealand Pharma A/S (ZLDPF) was upgraded to D+ from D on 5/14/2021 due to a large increase in the growth index, solvency index and valuation index. Earnings per share increased from -$1.5026 to -$0.9368, the quick ratio increased from 3.71 to 4.78, and EBIT increased 20.04% from -$52.88M to -$42.29M.
D
Sell
3/29/2021Downgrade
Zealand Pharma A/S (ZLDPF) was downgraded to D from D+ on 3/29/2021 due to a decline in the total return index and volatility index.
Zealand Pharma A/S (ZLDPF) was downgraded to D from D+ on 3/29/2021 due to a decline in the total return index and volatility index.
D
Sell
3/12/2021Upgraded
Zealand Pharma A/S (ZLDPF) was upgraded to D+ from D on 3/12/2021 due to an increase in the volatility index and valuation index.
Zealand Pharma A/S (ZLDPF) was upgraded to D+ from D on 3/12/2021 due to an increase in the volatility index and valuation index.
D
Sell
5/15/2020Downgrade
Zealand Pharma A/S (ZLDPF) was downgraded to D from D+ on 5/15/2020 due to a noticeable decline in the efficiency index, total return index and solvency index. Total capital declined 2.69% from $199.5M to $194.14M, and the quick ratio declined from 7.16 to 7.09.
Zealand Pharma A/S (ZLDPF) was downgraded to D from D+ on 5/15/2020 due to a noticeable decline in the efficiency index, total return index and solvency index. Total capital declined 2.69% from $199.5M to $194.14M, and the quick ratio declined from 7.16 to 7.09.
D
Sell
2/12/2020Downgrade
Zealand Pharma A/S (ZLDPF) was downgraded to D+ from C- on 2/12/2020 due to a decline in the volatility index.
Zealand Pharma A/S (ZLDPF) was downgraded to D+ from C- on 2/12/2020 due to a decline in the volatility index.
C
Hold
1/28/2020Upgraded
Zealand Pharma A/S (ZLDPF) was upgraded to C- from D+ on 1/28/2020 due to an increase in the total return index and volatility index.
Zealand Pharma A/S (ZLDPF) was upgraded to C- from D+ on 1/28/2020 due to an increase in the total return index and volatility index.
D
Sell
1/13/2020Downgrade
Zealand Pharma A/S (ZLDPF) was downgraded to D+ from C- on 1/13/2020 due to a decline in the total return index and growth index.
Zealand Pharma A/S (ZLDPF) was downgraded to D+ from C- on 1/13/2020 due to a decline in the total return index and growth index.
C
Hold
12/27/2019Upgraded
Zealand Pharma A/S (ZLDPF) was upgraded to C- from D+ on 12/27/2019 due to a large increase in the total return index, volatility index and growth index.
Zealand Pharma A/S (ZLDPF) was upgraded to C- from D+ on 12/27/2019 due to a large increase in the total return index, volatility index and growth index.
D
Sell
11/15/2019Downgrade
Zealand Pharma A/S (ZLDPF) was downgraded to D+ from C- on 11/15/2019 due to a significant decline in the valuation index, efficiency index and growth index. Total revenue declined 50.68% from $3M to $1.48M, and operating cash flow declined 6.8% from -$21.01M to -$22.43M.
Zealand Pharma A/S (ZLDPF) was downgraded to D+ from C- on 11/15/2019 due to a significant decline in the valuation index, efficiency index and growth index. Total revenue declined 50.68% from $3M to $1.48M, and operating cash flow declined 6.8% from -$21.01M to -$22.43M.
C
Hold
10/21/2019Upgraded
Zealand Pharma A/S (ZLDPF) was upgraded to C- from D+ on 10/21/2019 due to an increase in the volatility index and total return index.
Zealand Pharma A/S (ZLDPF) was upgraded to C- from D+ on 10/21/2019 due to an increase in the volatility index and total return index.
D
Sell
8/19/2019Downgrade
Zealand Pharma A/S (ZLDPF) was downgraded to D+ from C- on 8/19/2019 due to a decline in the growth index, efficiency index and valuation index. Operating cash flow declined 382.31% from $7.44M to -$21.01M, total capital declined 9.76% from $163.91M to $147.91M, and net income declined 6.34% from -$19.41M to -$20.64M.
Zealand Pharma A/S (ZLDPF) was downgraded to D+ from C- on 8/19/2019 due to a decline in the growth index, efficiency index and valuation index. Operating cash flow declined 382.31% from $7.44M to -$21.01M, total capital declined 9.76% from $163.91M to $147.91M, and net income declined 6.34% from -$19.41M to -$20.64M.
C
Hold
7/5/2019Upgraded
Zealand Pharma A/S (ZLDPF) was upgraded to C- from D+ on 7/5/2019 due to a large increase in the total return index and volatility index.
Zealand Pharma A/S (ZLDPF) was upgraded to C- from D+ on 7/5/2019 due to a large increase in the total return index and volatility index.
D
Sell
5/17/2019Downgrade
Zealand Pharma A/S (ZLDPF) was downgraded to D+ from C- on 5/17/2019 due to a noticeable decline in the growth index, efficiency index and valuation index. Total capital declined 4.26% from $171.21M to $163.91M, net income declined 3.17% from -$18.81M to -$19.41M, and earnings per share declined from -$0.6129 to -$0.6286.
Zealand Pharma A/S (ZLDPF) was downgraded to D+ from C- on 5/17/2019 due to a noticeable decline in the growth index, efficiency index and valuation index. Total capital declined 4.26% from $171.21M to $163.91M, net income declined 3.17% from -$18.81M to -$19.41M, and earnings per share declined from -$0.6129 to -$0.6286.
C
Hold
5/15/2019Upgraded
Zealand Pharma A/S (ZLDPF) was upgraded to C- from D+ on 5/15/2019 due to an increase in the volatility index and total return index.
Zealand Pharma A/S (ZLDPF) was upgraded to C- from D+ on 5/15/2019 due to an increase in the volatility index and total return index.
D
Sell
5/9/2019Upgraded
Zealand Pharma A/S (ZLDPF) was upgraded to D+ from D on 5/9/2019 due to a noticeable increase in the volatility index and total return index.
Zealand Pharma A/S (ZLDPF) was upgraded to D+ from D on 5/9/2019 due to a noticeable increase in the volatility index and total return index.
D
Sell
3/12/2019Downgrade
Zealand Pharma A/S (ZLDPF) was downgraded to D from D+ on 3/12/2019 due to a decline in the efficiency index, volatility index and valuation index. Net income declined 113.06% from $144.09M to -$18.81M, and total capital declined 11.44% from $193.32M to $171.21M.
Zealand Pharma A/S (ZLDPF) was downgraded to D from D+ on 3/12/2019 due to a decline in the efficiency index, volatility index and valuation index. Net income declined 113.06% from $144.09M to -$18.81M, and total capital declined 11.44% from $193.32M to $171.21M.
D
Sell
1/23/2019Downgrade
Zealand Pharma A/S (ZLDPF) was downgraded to D+ from C- on 1/23/2019 due to a decline in the total return index and volatility index.
Zealand Pharma A/S (ZLDPF) was downgraded to D+ from C- on 1/23/2019 due to a decline in the total return index and volatility index.
C
Hold
11/19/2018Upgraded
Zealand Pharma A/S (ZLDPF) was upgraded to C- from D- on 11/19/2018 due to a significant increase in the valuation index, efficiency index and growth index. EBIT increased 842.45% from -$21.12M to $156.84M, net income increased 807.7% from -$20.36M to $144.09M, and earnings per share increased from -$0.6635 to $4.6841.
Zealand Pharma A/S (ZLDPF) was upgraded to C- from D- on 11/19/2018 due to a significant increase in the valuation index, efficiency index and growth index. EBIT increased 842.45% from -$21.12M to $156.84M, net income increased 807.7% from -$20.36M to $144.09M, and earnings per share increased from -$0.6635 to $4.6841.
D
Sell
3/14/2018Downgrade
Zealand Pharma A/S (ZLDPF) was downgraded to D- from D on 3/14/2018 due to a significant decline in the growth index, total return index and volatility index. Operating cash flow declined 4,867.43% from $351.6 to -$16.76M, EBIT declined 188.37% from -$6.04M to -$17.41M, and earnings per share declined from -$0.2345 to -$0.5433.
Zealand Pharma A/S (ZLDPF) was downgraded to D- from D on 3/14/2018 due to a significant decline in the growth index, total return index and volatility index. Operating cash flow declined 4,867.43% from $351.6 to -$16.76M, EBIT declined 188.37% from -$6.04M to -$17.41M, and earnings per share declined from -$0.2345 to -$0.5433.
D
Sell
1/4/2018Downgrade
Zealand Pharma A/S (ZLDPF) was downgraded to D from D+ on 1/4/2018 due to a noticeable decline in the volatility index and total return index.
Zealand Pharma A/S (ZLDPF) was downgraded to D from D+ on 1/4/2018 due to a noticeable decline in the volatility index and total return index.
D
Sell
11/14/2017Upgraded
Zealand Pharma A/S (ZLDPF) was upgraded to D+ from D on 11/14/2017 due to a noticeable increase in the growth index, solvency index and efficiency index. Total revenue increased 296.04% from $1.6M to $6.33M, total capital increased 146.74% from $50.27M to $124.02M, and the quick ratio increased from 5.83 to 12.43.
Zealand Pharma A/S (ZLDPF) was upgraded to D+ from D on 11/14/2017 due to a noticeable increase in the growth index, solvency index and efficiency index. Total revenue increased 296.04% from $1.6M to $6.33M, total capital increased 146.74% from $50.27M to $124.02M, and the quick ratio increased from 5.83 to 12.43.
D
Sell
11/6/2017Downgrade
Zealand Pharma A/S (ZLDPF) was downgraded to D from D+ on 11/6/2017 due to a decline in the total return index and volatility index.
Zealand Pharma A/S (ZLDPF) was downgraded to D from D+ on 11/6/2017 due to a decline in the total return index and volatility index.
D
Sell
9/1/2017None
Zealand Pharma A/S (ZLDPF) was downgraded to D+ from U on 09/01/2017.
Zealand Pharma A/S (ZLDPF) was downgraded to D+ from U on 09/01/2017.
OTC PK
04/04/2025 10:28AM Eastern
Quotes delayed
